Global Anti Coccidial Drugs Market
Market Size in USD Million
CAGR :
% 
USD
1,242.48 Million
USD
3,103.95 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,242.48 Million |
 Market Size (Forecast Year) |
USD 3,103.95 Million |
 CAGR |
% |
| Major Markets Players |
|
Global Anti-Coccidial Drugs Market, By Type (Synthetic Drugs, Polyether Antibiotics or Ionophores, Combination Anti-Coccidial Drugs, Others), Animals (Swine, Fish, Cattle, Poultry, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Anti-Coccidial Drugs Market Analysis and Size
A major adoption of pet animals, which includes dogs, cats, and even horses, as companions of human beings has been witnessed during the recent years. The data stated by Kingsdale Animal Hospital in January 2022 showed that coccidia is one of the most common intestinal parasites found in dogs, and the occurrence of coccidia is 50 % in dogs, with a variation in incidence.
Data Bridge Market Research analyses a growth rate in the global anti-coccidial drugs market in the forecast period 2023-2030. The expected CAGR of the global anti-coccidial drugs market tends to be around 9.2% in the mentioned forecast period. The market was valued at USD 1,242.48 million in 2022 and would grow to USD 3,103.95 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anti-Coccidial Drugs Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Synthetic Drugs, Polyether Antibiotics or Ionophores, Combination Anti-Coccidial Drugs, Others), Animals (Swine, Fish, Cattle, Poultry, Others),End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Impextraco NV (Belgium), Vetoquinol (France), Phibro Animal Health Corporation (U.S.), Huvepharma (Bulgaria), Virbac (France), Bayer AG (Germany), Merck & Co., Inc (U.S.), Novartis AG (Switzerland)., Zoetis (U.S.)., Elanco (U.S.), Ceva (France)., ProBioGen AG (Germany) |
|
Market Opportunities |
|
Market Definition
Coccidiosis is caused due to single-celled parasites (protozoa) called Eimeria, which undergo a simple gut life cycle. Any such drug which is used to combat the progression of coccidiosis in birds or animals, both non-food producing and food-producing, is known as an anticoccidial. Its symptoms include weight loss, feces containing mucus or blood, dehydration, mild intermittent to severe diarrhea, and decreased breeding.
Global Anti-Coccidial Drugs Market Dynamics
Drivers
- Increasing share of animal ownership
Due to the promising economic condition, the highly developed economies represent a major large share of companion animal ownership. For instance, the Pet Food Manufacturers Association reported that in 2021, 17 million (59% of) households in the U.K. owned pets. These pet owners are more worried and aware of the safety of their pets. This creates an opportunity to diagnose fungal and bacterial diseases such as coccidiosis, which is an infection that is caused by the fungus coccidioides immitis among animals. This is projected to contribute to the overall market growth during the forecast period.
- Rising expenditure on pet healthcare
Pet owners are investing in their pets hugely, such as in health insurance for pets, leading to rising expenditure on their health, thus acting as a major driver for market growth. For instance, according to the North American Pet Health Insurance Association (NAPHIA), around 4.41 million pets were insured in North America at the end of 2021. Furthermore, as per American Pet Products Association, USD 123.6 billion was spent on pets and animals in the U.S. in 2021, which augmented from about USD 99.0 billion in 2020. This expenditure by pet owners is likely to boost market growth over the forecast period.
Opportunities
- The growing burden of coccidiosis in target animals
The wide prevcalence of coccidiosis among the target animals of specific age demands the wide availability of the anticoccidial drugs. For instance, Eimeria is a genus of apicomplexan parasites, that includes several species capable of causing the disease coccidiosis in animals such as dogs, cattle, poultry, cats, and smaller ruminants such as sheep and goats. According to the research article "Coccidiosis of Cattle" published in August 2022, approximately 20 or more Eimeria species have been identified in cattle feces worldwide. Thus, this factor creates more opportunities for market growth.
- Increasing prevalence of isospora species
According to the Merck and Co. Inc. data updated in August 2022 on "Coccidiosis of Cats and Dogs", the isospora species is a common coccidiosis of cats and dogs. Approximately every cat gets infected by isospora felis in its lifetime. Moreover, as per the source mentioned above, coccidiosis usually occurs in young animals in facilities with potential contamination and high population. Thus, this disease may become a problem in breeding or boarding catteries and kennels. This burden of coccidiosis among companion animals creates many different opportunities for developing anticoccidial drugs. This is projected to contribute to segment growth.
Restraints/Challenges
- Limited studies and surveys
There are very limited studies and surveys that are hampering the growth of the market. Not many studies and awareness have been spread about this disease, and thus, this hampers the market's growth.
- High cost of drugs
The huge expenditure associated with anti-coccidial medications hampers the market growth. Different polyether antibiotics or ionophores, combination anti-coccidial drugs are of high cost which restricts the growth of the market.
This global anti-coccidial drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti-coccidial drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Anti-Coccidial Drugs Market
The outbreak of COVID-19 showed an adverse impact on the global anti-coccidial drugs market . According to the article "The Initial Months of COVID-19: Dog Owners' Veterinary-Related Concerns," published in February 2021, dog owners feared that COVID-19 infection might lead to a decrease in disease diagnoses for pets. Moreover, the study showed that like many other professions, veterinarians were majorly impacted by the onset of COVID-19 in the initial phase of the pandemic. Thus, standard practices such as routine animal checkups, diagnoses, and surgeries were disturbed. These reduced services lowered the coccidiosis diagnosis, therefore, hampering the market growth.
But, in the post-pandemic era, poultry consumption and the adoption of companion animals increased. This led to a higher demand for diagnosis of poultry coccidiosis and companion animal coccidiosis. Thus, on the basis of above factors, the COVID-19 pandemic considerably impacted the market.
Recent Developments:
- In March 2022, Amlan International developed two new natural alternatives to antibiotics for poultry and livestock, such as Phylox Feed and NeutraPath. Phylox Feed is a natural alternative to anticoccidial drugs and vaccines, that can help producers to increase profitability.
Global Anti-Coccidial Drugs Market Scope
The global anti-coccidial drugs market is segmented on the basis of type, animals, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Synthetic Drugs
- Polyether Antibiotics or Ionophores
- Combination Anti-Coccidial Drugs
- Others
Animals
- Swine
- Fish
- Cattle
- Poultry
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Anti-Coccidial Drugs Market Regional Analysis/Insights
The global anti-coccidial drugs market is analysed and market size insights and trends are provided by type, animals, distribution channel and end-user as referenced above.
The major countries covered in the global anti-coccidial drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing positive growth for the global anticoccidial drugs market throughout the forecasted period due to increased healthcare and R&D expenditure and the presence of skilled professionals.
Asia-Pacific dominates the market due to increased poultry farming and increased awareness for anti-coccidial drugs through advertisement and media and rapidly improving healthcare infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anti-coccidial Drugs Market Share Analysis
The global anti-coccidial drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global anti-coccidial drugs market
Key players operating in the global anti-coccidial drugs market include:
- Impextraco NV (Belgium)
- Vetoquinol (France)
- Phibro Animal Health Corporation (U.S.)
- Huvepharma (Bulgaria)
- Virbac (France)
- Bayer AG (Germany)
- Merck & Co., Inc (U.S.),
- Novartis AG (Switzerland).
- Zoetis (U.S.)
- Elanco (U.S.)
- Ceva (France).
- ProBioGen AG (Germany)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ANTI-COCCIDIAL DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ANTI-COCCIDIAL DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ANTI-COCCIDIAL DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
6 INDUSTRY INSIGHTS
7 EPIDEMIOLOGY
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 MARKET ACCESS
9.1 10-YEAR MARKET FORECAST
9.2 ANNUAL NEW FDA APPROVED DRUGS
9.3 DRUGS MANUFACTURER AND DEALS
9.4 MAJOR DRUG UPTAKE
9.5 CURRENT TREATMENT PRACTICES
9.6 IMPACT OF UPCOMING THERAPY
10 PIPELINE ANALYSIS
Company Name Product Name
xx xx
xx xx
xx xx
xx xx
xx xx
xx xx
11 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY TYPE
11.1 OVERVIEW
11.2 SYNTHETIC DRUGS
11.2.1 ROBENIDINE
11.2.1.1. MARKET VALUE (USD MILLION)
11.2.1.2. MARKET VOLUME (UNITS)
11.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.2 AMPROLIUM
11.2.2.1. MARKET VALUE (USD MILLION)
11.2.2.2. MARKET VOLUME (UNITS)
11.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.3 ETHOPABATE
11.2.3.1. MARKET VALUE (USD MILLION)
11.2.3.2. MARKET VOLUME (UNITS)
11.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.4 APRINOCID
11.2.4.1. MARKET VALUE (USD MILLION)
11.2.4.2. MARKET VOLUME (UNITS)
11.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.5 CLOPIDOL
11.2.5.1. MARKET VALUE (USD MILLION)
11.2.5.2. MARKET VOLUME (UNITS)
11.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.6 DECOQUINATE
11.2.6.1. MARKET VALUE (USD MILLION)
11.2.6.2. MARKET VOLUME (UNITS)
11.2.6.3. AVERAGE SELLING PRICE (USD)
11.2.7 DICLAZURIL
11.2.7.1. MARKET VALUE (USD MILLION)
11.2.7.2. MARKET VOLUME (UNITS)
11.2.7.3. AVERAGE SELLING PRICE (USD)
11.2.8 DINITOLMIDE
11.2.8.1. MARKET VALUE (USD MILLION)
11.2.8.2. MARKET VOLUME (UNITS)
11.2.8.3. AVERAGE SELLING PRICE (USD)
11.2.9 HALOFUGINONE
11.2.9.1. MARKET VALUE (USD MILLION)
11.2.9.2. MARKET VOLUME (UNITS)
11.2.9.3. AVERAGE SELLING PRICE (USD)
11.2.10 DEQUINATE
11.2.10.1. MARKET VALUE (USD MILLION)
11.2.10.2. MARKET VOLUME (UNITS)
11.2.10.3. AVERAGE SELLING PRICE (USD)
11.2.11 NICARBAZIN
11.2.11.1. MARKET VALUE (USD MILLION)
11.2.11.2. MARKET VOLUME (UNITS)
11.2.11.3. AVERAGE SELLING PRICE (USD)
11.2.12 SULFONAMIDES
11.2.12.1. MARKET VALUE (USD MILLION)
11.2.12.2. MARKET VOLUME (UNITS)
11.2.12.3. AVERAGE SELLING PRICE (USD)
11.2.13 OTHER
11.3 POLYETHER ANTIBIOTICS OR IONOPHORES
11.3.1 MONOVALENT IONOPHORES
11.3.1.1. MONENSIN
11.3.1.1.1. MARKET VALUE (USD MILLION)
11.3.1.1.2. MARKET VOLUME (UNITS)
11.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.2. NARASIN
11.3.1.2.1. MARKET VALUE (USD MILLION)
11.3.1.2.2. MARKET VOLUME (UNITS)
11.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3. SALINOMYCIN
11.3.1.3.1. MARKET VALUE (USD MILLION)
11.3.1.3.2. MARKET VOLUME (UNITS)
11.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.4. OTHER
11.3.2 MONOVALENT GLYCOSIDIC IONOPHORES
11.3.2.1. MADURAMICIN
11.3.2.1.1. MARKET VALUE (USD MILLION)
11.3.2.1.2. MARKET VOLUME (UNITS)
11.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.2.2. SEMDURAMICIN
11.3.2.2.1. MARKET VALUE (USD MILLION)
11.3.2.2.2. MARKET VOLUME (UNITS)
11.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.2.3. OTHER
11.3.3 DIVALENT IONOPHORES
11.3.3.1. LASALOCID
11.3.3.1.1. MARKET VALUE (USD MILLION)
11.3.3.1.2. MARKET VOLUME (UNITS)
11.3.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.3.2. OTHER
11.4 COMBINATION ANTI-COCCIDIAL DRUGS
11.4.1 NICARBAZIN/NARASIN
11.4.1.1. MARKET VALUE (USD MILLION)
11.4.1.2. MARKET VOLUME (UNITS)
11.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.2 CLOPIDOL/ METHYL BENZOQUATE
11.4.2.1. MARKET VALUE (USD MILLION)
11.4.2.2. MARKET VOLUME (UNITS)
11.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.3 OTHER
11.5 VACCINES
11.5.1 COCCIVAC-B
11.5.2 COCCIVACT
11.5.3 PARACOX-5
11.5.4 OTHER
11.6 OTHERS
12 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY ANIMAL TYPE
12.1 OVERVIEW
12.2 LIVESTOCK
12.2.1 CATTLE
12.2.2 SHEEP & GOATS
12.2.3 SWINE
12.2.4 OTHERS
12.3 POULTRY
12.3.1 CHICKENS
12.3.1.1. BROILERS
12.3.1.2. LAYERS
12.3.2 TURKEYS
12.3.3 DUCKS
12.3.4 OTHERS
12.4 FISH
12.5 OTHERS
13 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 BRANDED
13.2.1 MAXIBAN
13.2.2 LERBEK
13.2.3 DECCOX
13.2.4 AMPROL
13.2.5 CORID
13.2.6 CLINACOX
13.2.7 AVATEC
13.2.8 MONTEBAN
13.2.9 COBAN
13.2.10 OTHER
13.3 GENERICS
14 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 POWDERS
14.2.2 GRANULES
14.2.3 LIQUIDS
14.3 INJECTION
14.3.1 INTRAMUSCULARLY
14.3.2 SUBCUTANEOUSLY
14.4 OTHER
15 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 VETERINARY HOSPITALS
15.3 VETERINARY CARE
15.4 HOG PRODUCTION FARM
15.5 LIVESTOCK FARMS
15.6 POULTRY FARMS
15.7 OTHERS
16 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL PHARMACY
16.3.1 HOSPITAL ASSOCIATED PHARMACY
16.3.2 DRUG STORE
16.3.3 ONLINE PHARMACY
16.3.4 OTHER
16.4 OTHERS
17 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY GEOGRAPHY
18.1 GLOBAL ANTI-COCCIDIAL DRUGS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1.1 NORTH AMERICA
18.1.1.1. U.S.
18.1.1.2. CANADA
18.1.1.3. MEXICO
18.1.2 EUROPE
18.1.2.1. GERMANY
18.1.2.2. U.K.
18.1.2.3. ITALY
18.1.2.4. FRANCE
18.1.2.5. SPAIN
18.1.2.6. RUSSIA
18.1.2.7. SWITZERLAND
18.1.2.8. TURKEY
18.1.2.9. BELGIUM
18.1.2.10. NETHERLANDS
18.1.2.11. DENMARK
18.1.2.12. SWEDEN
18.1.2.13. POLAND
18.1.2.14. NORWAY
18.1.2.15. FINLAND
18.1.2.16. REST OF EUROPE
18.1.3 ASIA-PACIFIC
18.1.3.1. JAPAN
18.1.3.2. CHINA
18.1.3.3. SOUTH KOREA
18.1.3.4. INDIA
18.1.3.5. SINGAPORE
18.1.3.6. THAILAND
18.1.3.7. INDONESIA
18.1.3.8. MALAYSIA
18.1.3.9. PHILIPPINES
18.1.3.10. AUSTRALIA
18.1.3.11. NEW ZEALAND
18.1.3.12. VIETNAM
18.1.3.13. TAIWAN
18.1.3.14. REST OF ASIA-PACIFIC
18.1.4 SOUTH AMERICA
18.1.4.1. BRAZIL
18.1.4.2. ARGENTINA
18.1.4.3. PERU
18.1.4.4. REST OF SOUTH AMERICA
18.1.5 MIDDLE EAST AND AFRICA
18.1.5.1. SOUTH AFRICA
18.1.5.2. EGYPT
18.1.5.3. BAHRAIN
18.1.5.4. UNITED ARAB EMIRATES
18.1.5.5. KUWAIT
18.1.5.6. OMAN
18.1.5.7. QATAR
18.1.5.8. SAUDI ARABIA
18.1.5.9. REST OF MEA
18.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, SWOT AND DBMR ANALYSIS
20 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, COMPANY PROFILE
20.1 IMPEXTRACO NV
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPEMNTS
20.2 VETOQUINOL
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPEMNTS
20.3 PHIBRO ANIMAL HEALTH CORPORATION
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPEMNTS
20.4 HUVEPHARMA
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPEMNTS
20.5 VIRBAC
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPEMNTS
20.6 MERCK & CO.,INC
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPEMNTS
20.7 ZOETIS
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPEMNTS
20.8 ELANCO
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPEMNTS
20.9 CEVA
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPEMNTS
20.1 HIPRA
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPEMNTS
20.11 HUVEPHARMA
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPEMNTS
20.12 AURORA PHARMACEUTICAL, INC.
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPEMNTS
20.13 BOEHRINGER INGELHEIM LTD
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPEMNTS
20.14 CHINA ANIMAL HUSBANDRY GROUP
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPEMNTS
20.15 BAYER AG
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPEMNTS
20.16 BIOPROPERTIES PTY LTD
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPEMNTS
20.17 KEMIN INDUSTRIES, INC
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPEMNTS
20.18 QILU ANIMAL HEALTH PRODUCTS CO., LTD.
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPEMNTS
20.19 VENKYS INDIA
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPEMNTS
20.2 VETBIOCHEM INDIA PRIVATE LIMITED
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPEMNTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
